{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:39:25Z","timestamp":1794443965706,"version":"4.9.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1053\/j.seminhematol.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:36:06Z","timestamp":1770136566000},"page":"392-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Emerging technologies for minimal residual disease detection in hematologic malignancies"],"prefix":"10.1053","volume":"62","author":[{"given":"Daniel J.","family":"Groso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-8836","authenticated-orcid":false,"given":"David G.","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.seminhematol.2026.02.001_bib0001","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V77.2.331.331","article-title":"Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients","volume":"77","author":"Yokota","year":"1991","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.02.001_bib0002","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood.V77.9.1989.1989","article-title":"Detection of T-cell receptor gamma chain V gene rearrangements using the polymerase chain reaction: application to the study of clonal disease cells in acute lymphoblastic leukemia","volume":"77","author":"Taylor","year":"1991","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.02.001_bib0003","first-page":"47","article-title":"Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction","volume":"6","author":"van Dongen","year":"1992","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0004","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood.V78.1.192.192","article-title":"Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction","volume":"78","author":"Trainor","year":"1991","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.02.001_bib0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0006","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1365-2141.2003.03974.x","article-title":"Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia","volume":"120","author":"Krampera","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1112616","article-title":"Measurable residual disease in chronic lymphocytic leukemia","volume":"13","author":"Benintende","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.02.001_bib0008","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2002.20.4.1094","article-title":"Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia","volume":"20","author":"Mortuza","year":"2002","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.02.001_bib0009","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.02.001_bib0010","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.02.001_bib0011","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA approval: blinatumomab for patients with b-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease","volume":"25","author":"Jen","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.02.001_bib0012","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/1078-0432.CCR-22-3579","article-title":"Minimal residual disease data in hematologic malignancy drug applications and labeling: an FDA perspective","volume":"29","author":"Baines","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.02.001_bib0013","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.02.001_bib0014","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0015","unstructured":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. National Comprehensive Cancer Network; 2025. (NCCN Clinical Practice Guidelines in Oncology). Report No.: Version 1.2026. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0016","unstructured":"Acute Lymphoblastic Leukemia. National Comprehensive Cancer Network; 2025. (NCCN Clinical Practice Guidelines in Oncology). Report No.: Version 2.2025. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0017","unstructured":"Multiple Myeloma. National Comprehensive Cancer Network; 2025. (NCCN Clinical Practice Guidelines in Oncology). Report No.: Version 3.2026. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0018","unstructured":"Acute Myeloid Leukemia. National Comprehensive Cancer Network; 2025. (NCCN Clinical Practice Guidelines in Oncology). Report No.: Version 2.2026. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0019","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jmoldx.2021.09.006","article-title":"Ig gene clonality analysis using next-generation sequencing for improved minimal residual disease detection with significant prognostic value in multiple myeloma patients","volume":"24","author":"Ha","year":"2022","journal-title":"J Mol Diagn"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.02.001_bib0020","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/1078-0432.CCR-20-2995","article-title":"Capture rate of V(D)J sequencing for minimal residual disease detection in multiple myeloma","volume":"28","author":"Hultcrantz","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0285696","article-title":"Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes\u2013a feasibility study","volume":"18","author":"Marx","year":"2023","journal-title":"Plos One"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0022","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.02.001_bib0023","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0024","doi-asserted-by":"crossref","unstructured":"Sommer C, Mack HID, Killer MC, et al. Detection of minimal residual disease in circulating cell-free DNA in acute myeloid leukemia. Sci Rep. 2025;15(1):32679.","DOI":"10.1038\/s41598-025-20589-3"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.02.001_bib0025","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.3390\/cancers14143307","article-title":"Monitoring of measurable residual disease using circulating DNA after allogeneic hematopoietic cell transplantation","volume":"14","author":"Waterhouse","year":"2022","journal-title":"Cancers"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1252258","article-title":"Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges","volume":"15","author":"\u00c1lvarez","year":"2024","journal-title":"Front Immunol"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.02.001_bib0027","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","article-title":"Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia","volume":"135","author":"Hasserjian","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.02.001_bib0028","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.02.001_bib0029","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.02.001_bib0030","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.3390\/cancers13215431","article-title":"Molecular minimal residual disease detection in acute myeloid leukemia","volume":"13","author":"Vonk","year":"2021","journal-title":"Cancers"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102106","article-title":"Liquid biopsy in lymphoma: molecular methods and clinical applications","volume":"91","author":"Cirillo","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.02.001_bib0032","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.3390\/ijms26104869","article-title":"Liquid biopsy in B and T cell lymphomas: from bench to bedside","volume":"26","author":"Almasri","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0033","doi-asserted-by":"crossref","unstructured":"Lauer EM, Mutter J, Scherer F. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. Leukemia. 2022;36(9):2151\u201364.","DOI":"10.1038\/s41375-022-01618-w"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.02.001_bib0034","first-page":"416","article-title":"Role of cell-free DNA in haematological malignancies","volume":"53","author":"Lim","year":"2021","journal-title":"Pathology (Phila)"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101237","article-title":"Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future","volume":"68","author":"Li","year":"2024","journal-title":"Blood Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0036","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41375-021-01316-z","article-title":"Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns","volume":"36","author":"Bo\u017ei\u0107","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16685-3","article-title":"Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia","volume":"12","author":"Shao","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.02.001_bib0038","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-20-2558","article-title":"Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study","volume":"27","author":"Rivas-Delgado","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.02.001_bib0039","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.seminhematol.2023.06.006","article-title":"Blood has never been thicker: cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas","volume":"60","author":"Meriranta","year":"2023","journal-title":"Semin Hematol"},{"issue":"7761","key":"10.1053\/j.seminhematol.2026.02.001_bib0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.02.001_bib0041","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-020-0291-8","article-title":"Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis","volume":"10","author":"Dispenzieri","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.02.001_bib0042","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmoldx.2020.04.002","article-title":"Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma","volume":"22","author":"Martins","year":"2020","journal-title":"J Mol Diagn JMD"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.02.001_bib0043","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.001_bib0044","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.02.001_bib0045","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","article-title":"Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins","volume":"66","author":"Zajec","year":"2020","journal-title":"Clin Chem"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.02.001_bib0046","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1002\/cam4.4254","article-title":"Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma","volume":"10","author":"Foureau","year":"2021","journal-title":"Cancer Med"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.02.001_bib0047","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood.2024024995","article-title":"Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma","volume":"144","author":"Puig","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.02.001_bib0048","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood.2024024041","article-title":"Mass spectrometry\u2013based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma","volume":"144","author":"Kubicki","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.02.001_bib0050","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-23-2767","article-title":"Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)","volume":"30","author":"Fan","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.02.001_bib0051","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/clinchem\/hvab017","article-title":"Clonotypic features of rearranged immunoglobulin genes yield personalized biomarkers for minimal residual disease monitoring in multiple myeloma","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin Chem"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.02.001_bib0052","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.3390\/cancers13184582","article-title":"Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges","volume":"13","author":"Riva","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.02.001_bib0053","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41375-022-01647-5","article-title":"Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia","volume":"36","author":"R\u00f6hnert","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0054","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2025.06.004","article-title":"Measurable residual disease monitoring in acute myeloid leukaemia: techniques, timing and therapeutic implications","author":"Croese","year":"2025","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0055","doi-asserted-by":"crossref","unstructured":"van Dongen JJM, Lhermitte L, B\u00f6ttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908\u201375.","DOI":"10.1038\/leu.2012.120"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.02.001_bib0056","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.02.001_bib0057","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.001_bib0058","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/ijms25052847","article-title":"Phenotypic analysis of hematopoietic stem and progenitor cell populations in acute myeloid leukemia based on spectral flow cytometry, a 20-color panel, and unsupervised learning algorithms","volume":"25","author":"Matthes","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0059","doi-asserted-by":"crossref","unstructured":"Zhang Z, Wilhelm M, Sieber I, D\u00f6hner H, Feuring M. Development of a 29-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease and leukemic stem cells in acute myeloid leukemia. Cytometry A. 2025;107(9):597\u2013613.","DOI":"10.1002\/cyto.a.24958"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.02.001_bib0060","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/ijms25042150","article-title":"Minimal residual disease in acute myeloid leukemia: old and new concepts","volume":"25","author":"Chea","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.02.001_bib0061","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1515\/cclm-2025-0017","article-title":"Assessing the clinical applicability of dimensionality reduction algorithms in flow cytometry for hematologic malignancies","volume":"63","author":"Park","year":"2025","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.02.001_bib0062","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/cancers17030483","article-title":"Machine learning methods in clinical flow cytometry","volume":"17","author":"Spies","year":"2025","journal-title":"Cancers"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.02.001_bib0063","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.3390\/ijms21155406","article-title":"Functional imaging for therapeutic assessment and minimal residual disease detection in multiple myeloma","volume":"21","author":"Jamet","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.02.001_bib0064","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1182\/bloodadvances.2024015686","article-title":"Fifteen year of use of functional imaging in multiple myeloma: where we started from and where are we going","volume":"9","author":"Zamagni","year":"2025","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2021.109793","article-title":"Overview and recent advances in PET\/CT imaging in lymphoma and multiple myeloma","volume":"141","author":"Zanoni","year":"2021","journal-title":"Eur J Radiol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.001_bib0066","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/jmri.26848","article-title":"MRI and PET\/MRI in hematologic malignancies","volume":"51","author":"Mayerhoefer","year":"2020","journal-title":"J Magn Reson Imaging JMRI"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.02.001_bib0067","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.02.001_bib0068","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1007\/s00330-023-09593-1","article-title":"Hybrid simultaneous whole-body 2-[18F]FDG-PET\/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results","volume":"33","author":"Jamet","year":"2023","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.02.001_bib0069","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2214\/AJR.21.26381","article-title":"Comparative performance of whole-body MRI and FDG PET\/CT in evaluation of multiple myeloma treatment response: systematic review and meta-analysis","volume":"218","author":"Rama","year":"2022","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.02.001_bib0070","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s00277-020-04265-2","article-title":"Prospective comparison of 18-FDG PET\/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma","volume":"99","author":"Mesguich","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2025.109019","article-title":"Radiomics feature analysis for survival prediction in multiple myeloma: an automated PET\/CT approach","volume":"271","author":"Guinea-P\u00e9rez","year":"2025","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0072","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45215-y","article-title":"Performance of baseline FDG-PET\/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial","volume":"13","author":"Bodet-Milin","year":"2023","journal-title":"Sci Rep"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.02.001_bib0073","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.122.264972","article-title":"New developments in myeloma treatment and response assessment","volume":"64","author":"Kraeber-Bod\u00e9r\u00e9","year":"2023","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.02.001_bib0074","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0075","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-023-00794-x","article-title":"Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","volume":"13","author":"Fonseca","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.02.001_bib0076","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0077","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1097\/RLU.0000000000005426","article-title":"CXCR4-targeted PET imaging in hematologic malignancies: a systematic review and meta-analysis","volume":"50","author":"Chavoshi","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.001_bib0078","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S2352-3026(23)00030-3","article-title":"European Association of Nuclear Medicine (EANM) focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours","volume":"10","author":"Nanni","year":"2023","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.02.001_bib0079","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00259-024-07036-7","article-title":"CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies","volume":"52","author":"Huang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.02.001_bib0080","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1158\/0008-5472.CAN-20-0283","article-title":"Mathematical modeling provides evidence for niche competition in human AML and serves as a tool to improve risk stratification","volume":"80","author":"Stiehl","year":"2020","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0081","doi-asserted-by":"crossref","unstructured":"Hoffmann H, Thiede C, Glauche I, Bornhaeuser M, Roeder I. Differential response to cytotoxic therapy explains treatment dynamics of acute myeloid leukaemia patients: insights from a mathematical modelling approach. J R Soc Interface. 2020;17(170):20200091.","DOI":"10.1098\/rsif.2020.0091"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2025.102526","article-title":"Therapeutic hurdles in acute myeloid leukemia: leukemic stem cells, inflammation and immune dysfunction","volume":"82","author":"Wang","year":"2025","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0083","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.241202","article-title":"Cellular automata modelling of leukaemic stem cell dynamics in acute myeloid leukaemia: insights into predictive outcomes and targeted therapies","volume":"12","author":"Saikawa","year":"2025","journal-title":"R Soc Open Sci"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0084","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13059-023-03031-7","article-title":"Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML","volume":"24","author":"Zhang","year":"2023","journal-title":"Genome Biol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.02.001_bib0085","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.3390\/cancers13091995","article-title":"Exploiting clonal evolution to improve the diagnosis and treatment efficacy prediction in pediatric AML","volume":"13","author":"Bertuccio","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.02.001_bib0086","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1038\/s41467-022-33244-6","article-title":"Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia","volume":"13","author":"Huang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2026.02.001_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103348","article-title":"Measurable residual disease in hematologic malignancies: a biomarker in search of a standard","volume":"86","author":"Chandhok","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.02.001_bib0088","doi-asserted-by":"crossref","first-page":"e586","DOI":"10.1016\/S1470-2045(25)00426-7","volume":"26","author":"Sanz","year":"2025","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.02.001_bib0089","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35960","article-title":"Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium","volume":"131","author":"Boyiadzis","year":"2025","journal-title":"Cancer"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.02.001_bib0090","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"key":"#cr-split#-10.1053\/j.seminhematol.2026.02.001_bib0091.1","unstructured":"U.S. Food and Drug Administration. Final Summary Minutes of the Oncologic Drugs Advisory Committee Meeting, April 12, 2024. Center for Drug Evaluation and Research, U.S. Food and Drug Administration"},{"key":"#cr-split#-10.1053\/j.seminhematol.2026.02.001_bib0091.2","unstructured":"2024. Available from: https:\/\/www.fda.gov\/media\/180108\/download. (Accessed 2025 Nov 14)."},{"issue":"11","key":"10.1053\/j.seminhematol.2026.02.001_bib0092","doi-asserted-by":"crossref","first-page":"e586","DOI":"10.1016\/S1470-2045(25)00426-7","volume":"26","author":"Sanz","year":"2025","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.02.001_bib0093","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35960","article-title":"Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium","volume":"131","author":"Boyiadzis","year":"2025","journal-title":"Cancer"},{"issue":"7762","key":"10.1053\/j.seminhematol.2026.02.001_bib0094","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41586-019-1310-4","article-title":"Genetic analyses of diverse populations improves discovery for complex traits","volume":"570","author":"Wojcik","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.02.001_bib0095","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nat Genet"},{"issue":"7624","key":"10.1053\/j.seminhematol.2026.02.001_bib0096","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/538161a","article-title":"Genomics is failing on diversity","volume":"538","author":"Popejoy","year":"2016","journal-title":"Nature"},{"issue":"7793","key":"10.1053\/j.seminhematol.2026.02.001_bib0097","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/d41586-020-00082-9","article-title":"Genomics: data sharing needs an international code of conduct","volume":"578","author":"Phillips","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.02.001_bib0098","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5858\/arpa.2019-0493-CP","article-title":"Participation in the College of American Pathologists Laboratory Accreditation Program decreases variability in B-lymphoblastic leukemia and plasma cell myeloma flow cytometric minimal residual disease testing: a follow-up survey","volume":"145","author":"Hupp","year":"2021","journal-title":"Arch Pathol Lab Med"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632600003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632600003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:06:41Z","timestamp":1778728001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719632600003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S003719632600003X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.02.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging technologies for minimal residual disease detection in hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}